TABLE 1.

Previously characterized HCMV clinical isolates

Isolate	Genotypea	Phenotypeb,c	IC50 (μM)b	Reference
MR11979	POL C412 POL M802 UL97 W603	GCV, FOS, and HPMPC resistant	GCV, >50; FOS, 870; HPMPC, 24	6
V379354 (C9208)e	WTd	GCV, FOS, and HPMPC sensitive	GCV, 3.42; FOS, 96.54; HPMPC, 0.30	15
V917401 (C9209)e	POL A552 POL A841 UL97 V460	GCV resistant; FOS and HPMPC sensitive	GCV, 43.06; FOS, 179.91; HPMPC, 0.6	15
K8313	NDf	Partially GCV resistant	GCV, 12	27
MAL	ND	Partially GCV resistant	GCV, 7.93	Table 3
OBR	UL97 S595	GCV resistant, FOS and HPMPC sensitive	GCV, 20; FOS, 150; HPMPC, 0.5	23
MG	WT	GCV, FOS, and HPMPC sensitive	GCV, 5; FOS, 100; HPMPC, 0.5	23
GU	ND	GCV resistant, FOS sensitive	GCV, 13.2; FOS, 198.4g	Table 3
JD	WT	GCV sensitive, FOS sensitive	GCV, 3.0; FOS, 149.9g	Table 3

^aGenotypes were determined by sequencing the UL97 and POL regions of the viral isolates. 

^bPhenotypes and IC₅₀s were determined by plaque reduction assays. 

^cGCV, ganciclovir; FOS, foscarnet; HPMPC, cidofovir. 

^dWT, wild type. 

^eC9208 and C9209 are plaque-purified derivatives of V379354 and V917401, respectively. 

^fND, not determined. 

^gUnpublished foscarnet plaque reduction assay data.